Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Operating Leases (2019 - 2022)

Historic Operating Leases for Aytu Biopharma (AYTU) over the last 4 years, with Q1 2022 value amounting to $2.4 million.

  • Aytu Biopharma's Operating Leases fell 3639.97% to $2.4 million in Q1 2022 from the same period last year, while for Mar 2022 it was $2.4 million, marking a year-over-year decrease of 3639.97%. This contributed to the annual value of $2.6 million for FY2021, which is 26193.1% up from last year.
  • Per Aytu Biopharma's latest filing, its Operating Leases stood at $2.4 million for Q1 2022, which was down 3639.97% from $2.7 million recorded in Q4 2021.
  • Aytu Biopharma's Operating Leases' 5-year high stood at $3.8 million during Q1 2021, with a 5-year trough of $211056.0 in Q4 2020.
  • Its 4-year average for Operating Leases is $1.6 million, with a median of $1.6 million in 2020.
  • Its Operating Leases has fluctuated over the past 5 years, first plummeted by 4371.84% in 2020, then surged by 118686.23% in 2021.
  • Over the past 4 years, Aytu Biopharma's Operating Leases (Quarter) stood at $375000.0 in 2019, then tumbled by 43.72% to $211056.0 in 2020, then surged by 1186.86% to $2.7 million in 2021, then fell by 11.41% to $2.4 million in 2022.
  • Its Operating Leases stands at $2.4 million for Q1 2022, versus $2.7 million for Q4 2021 and $2.8 million for Q3 2021.